Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence
Polymyxin B has resurged in recent years as a last resort therapy for Gram-negative multidrug-resistant (MDR) and extremely drug resistant (XDR) infections. Understanding newer evidence on polymyxin B is necessary to guide clinical decision making. Here, we present a literature review of polymyxin B...
Saved in:
Main Authors: | Suneel Kumar Garg, Omender Singh, Deven Juneja, Niraj Tyagi, Amandeep Singh Khurana, Amit Qamra, Salman Motlekar, Hanmant Barkate |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Critical Care Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2017/3635609 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The second life of polymyxins
by: Ageevets V.A.
Published: (2024-09-01) -
Association and application in XDR and MR data
by: Tao LIU, et al.
Published: (2019-04-01) -
Treatment outcomes among children and adolescents with extensively drug-resistant (XDR) and pre-XDR tuberculosis: Systematic review and meta-analysis.
by: Jayadeep Patra, et al.
Published: (2025-01-01) -
Extensively Drug-Resistant (XDR) Enteric Fever in Children
by: Sana Ashraf, et al.
Published: (2025-01-01) -
Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin
by: Jingli Lu, et al.
Published: (2025-01-01)